Evidence map›Paper›PMID 39568653›Full record

ArticleJACC. Advances2024

Participant Engagement and Preference Study for Clinical Outcomes Associated With Atrial Fibrillation: The PEARL-AF Study.

Shelby D Reed, Josephine L Harrington, Daniel P Morin, Samir F Saba, Jay Alan Montgomery, Robert W Harrison, Daniel R Frisch, Thomas Viethen, Miriam Tamm, Jessica Xiao and 6 more

Abstract read
In one paragraph

Article in JACC. Advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Shelby D ReedDuke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
Josephine L HarringtonDuke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
Daniel P MorinDepartment of Cardiology, Ochsner Medical Center, New Orleans, Los Angeles, USA.
Samir F SabaUniversity of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Jay Alan MontgomeryVanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, USA.
Robert W HarrisonDepartment of Medicine, Duke University Health System, Durham, North Carolina, USA.
Daniel R FrischDivision of Cardiology, Thomas Jefferson Medical Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Thomas ViethenBayer AG, Research & Development, Wuppertal, Germany.
Miriam TammBayer AG, Research & Development, Wuppertal, Germany.
Jessica XiaoBayer U.S. LLC, Whippany, New Jersey, USA.
Hardi MundlBayer AG, Research & Development, Wuppertal, Germany.
Rosa CoppolecchiaBayer U.S. LLC, Whippany, New Jersey, USA.
Jui-Chen YangDuke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
Matthew J WallaceDuke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
Juan Marcos GonzalezDuke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
Manesh R PatelDuke Clinical Research Institute, Duke University, Durham, North Carolina, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Quantifying patients' preferences for health outcomes associated with atrial fibrillation (AF) and its treatments offers a replicable approach to considering the patient perspective in regulatory decision-making. Objective: The authors conducted a preference survey to estimate the relative importance of AF-related events for use in clinical trial analyses to estimate net health benefits with anticoagulants. Methods: The survey included nontechnical descriptions of three severities of stroke, systemic embolism, myocardial infarction (MI) with or without subsequent heart failure (HF), major bleeding, clinically relevant nonmajor bleeding, and death. A best-worst scaling question format was used in which patients were shown 10 sets of four events and asked to select what they considered to be most and least serious. Results: One thousand twenty-eight patients, mean age 69.2 years, 40.4% female, completed the survey. Best-worst scaling importance weights were significantly different across all events except between major bleeding and MI with HF. Death was considered the most serious (reweighted to 1), followed by severe disabling stroke (0.83), then major bleeding (0.53) or MI with HF (0.50), moderate-severity stroke (0.28) and systemic embolism (0.13). Clinically relevant nonmajor bleeding, MI without HF, and minor stroke (0.10, 0.06, and 0.04, respectively) were considered least serious. Events ordered by importance were consistent across age, sex, and race, but relative weights across events varied by sex and race. Conclusions: Patients expressed relatively high levels of concern about major bleeding compared to moderate-severity stroke or systemic embolism, endpoints frequently used in AF trials. Estimated weights could be used in patient-centered net-benefit determinations for AF therapies.

Indexed as

atrial fibrillationnet clinical benefitpatient-centered drug developmentpatient preferences

Identifiers

PMID39568653
PMCPMC11576534

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.